2026/0147 - Invitation to submit proposals under framework agreement(s) 2023/438 - Human plasma derivatives and 2023/671 - Various medicines for the acquisition of plasma-derived medicines

This tender, identified as 2026/0147, is an invitation to submit proposals for the acquisition of medicines derived from human plasma. The procurement is conducted under the framework agreements 2023/438 (specifically for Human Plasma Derivatives) and 2023/671 (for Various Medicines). This indicates that the contracting authority is leveraging existing framework agreements to streamline the procurement process for these specific pharmaceutical products. The focus is on medicines derived from human plasma, which are often used to treat rare diseases, immune deficiencies, and bleeding disorders. The tender seeks proposals from suppliers who are party to or eligible to bid under these framework agreements. The specific medicines required, quantities, delivery schedules, and any additional technical or regulatory requirements will be detailed in the full tender documentation. This process aims to ensure a consistent and reliable supply of critical plasma-derived medications.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 7,880.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.